Piper Jaffray analyst Tyler Van Buren said Bluebird Bio made substantial progress in Q2 and reported what he believes were very positive datasets across its key development programs. The analyst, who contends that Bluebird is “entering an exciting period of time,” recommends that investors own the shares to realize the additional value that will be generated from LentiGlobin, bb2121(7), and Lenti-D as the company has the potential for its first three product approvals over the period of 2019-2020. Van Buren maintains an Overweight rating on Bluebird Bio shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.